Windtree Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Windtree Therapeutics şirketinin toplam hissedar öz sermayesi $3.5M ve toplam borcu $1.7M olup, bu da borç-öz sermaye oranını 48.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $28.7M ve $25.2M dir.

Anahtar bilgiler

48.7%

Borç/özkaynak oranı

US$1.70m

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.80m
Eşitlik	US$3.49m
Toplam yükümlülükler	US$25.21m
Toplam varlıklar	US$28.71m

Son finansal sağlık güncellemeleri

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: WINT 'nin kısa vadeli varlıkları ( $2.1M ) kısa vadeli yükümlülüklerini ( $8.8M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: WINT 'un kısa vadeli varlıkları ( $2.1M ) uzun vadeli yükümlülüklerini ( $16.4M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: WINT şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: WINT şirketinin borç/öz sermaye oranı son 5 yılda 39.6% seviyesinden 48.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: WINT son raporlanan serbest nakit akışına göre 2 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: WINT serbest nakit akışı tahminlerine göre 2 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Windtree Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Windtree Therapeutics, Inc. announced delayed 10-Q filing

Windtree Therapeutics Regains Compliance with Nasdaq

Windtree Therapeutics Approves 1-for-18 Reverse Stock Split and Expects Compliance with Listing Requirements of the $1.00 Minimum Bid Price Requirement by The Nasdaq Capital Market

Windtree Therapeutics, Inc. announced delayed annual 10-K filing

Windtree Therapeutics Receives Non-Compliance Notice from Nasdaq

Nasdaq Grants Windtree Therapeutics 180-Day Extension to Regain Compliance

Recent updates

Windtree Therapeutics, Inc. Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong

Windtree Therapeutics, Inc. Initiates Enrollment in the SEISMiC C Trial in SCAI Stage C Cardiogenic Shock

Windtree Therapeutics, Inc. Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Windtree Announces Positive Topline Results from Its Phase 2B Seismic Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc., Annual General Meeting, Sep 24, 2024

Windtree Therapeutics, Inc. announced delayed 10-Q filing

Windtree Therapeutics, Inc. announced that it has received $1 million in funding

New major risk - Share price stability

Windtree Therapeutics, Inc. has withdrawn its Follow-on Equity Offering.

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Windtree Therapeutics, Inc. announced that it has received $3.4 million in funding

New major risk - Revenue and earnings growth

Price target decreased by 89% to US$18.00

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering.

Windtree Therapeutics Regains Compliance with Nasdaq

Windtree Therapeutics Approves 1-for-18 Reverse Stock Split and Expects Compliance with Listing Requirements of the $1.00 Minimum Bid Price Requirement by The Nasdaq Capital Market

Windtree Therapeutics, Inc. (NasdaqCM:WINT) acquired All of the assets of Varian Biopharmaceuticals, Inc.

Windtree Therapeutics, Inc. announced delayed annual 10-K filing

Windtree Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Revenue and earnings growth

Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.054024 million.

New major risk - Share price stability

Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer

Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators

Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors

Windtree Therapeutics, Inc. Announces Chief Financial Official Officer Changes

Nasdaq Grants Windtree Therapeutics 180-Day Extension to Regain Compliance

Price target decreased to US$3.00

Windtree Therapeutics, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2022

Windtree Therapeutics, Inc. Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (Seismic) Published in the European Journal of Heart Failure

Windtree Therapeutics, Inc. Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

Windtree Therapeutics, Inc. Reports Impairment for the Second Quarter Ended June 30, 2022

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Windtree Therapeutics Receives Non-Compliance Letter from Nasdaq

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

Windtree Therapeutics, Inc. Announces Not Stand for Re-Election of Evan Loh from Board

Windtree Therapeutics, Inc., Annual General Meeting, Jun 07, 2022

Price target decreased to US$5.50

Windtree Therapeutics, Inc. Announces Positive Topline Results from Its Phase 2 Seismic Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Completes Enrollment in its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Windtree Therapeutics, Inc. Announces Results of U.S. Hospital Claims Data Analysis Showing Hospital Inpatient Mortality and Length of Hospital Stay for Cardiogenic Shock Patients

Independent Chairman of the Board recently bought US$95k worth of stock

Price target decreased to US$8.25

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Independent Non-Executive Director Bruce Peacock has left the company

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Independent Chairman of the Board recently bought US$354k worth of stock

New 90-day low: US$4.94

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Windtree Therapeutics, Inc. Announces Executive Changes

Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development

Windtree Therapeutics, Inc.(NasdaqCM:WINT) dropped from S&P TMI Index

Windtree Therapeutics, Inc. Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$4.98

Windtree Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients

Windtree Therapeutics, Inc. Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$5.94

Earnings released

New 90-day high - US$9.90

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin